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calized intracellularly revealed a dose-dependent increase 
of TiO 2 -positive cells. This points to the fact that in humans 
with a leaky intestinal barrier (such as IBD patients), TiO 2 mi-
croparticles may be taken up by macrophages and intestinal 
epithelial cells, may activate the inflammasome and induce 
IL-1  and IL-18 secretion. This may aggravate inflammation 
in susceptible individuals.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Intestinal epithelial cells (IECs) form a single layer on 
the surface of the intestinal mucosa and the primary bar-
rier against the content of the gut lumen. They protect the 
underlying tissue and the entire organism from poten-
tially harmful microorganisms, particles or larger mole-
cules. IECs secrete antimicrobial substances such as de-
fensins  [1, 2] and communicate with the immune cells of 
the intestinal mucosa via a high number of soluble me-
diators such as chemokines and cytokines. In patients 
with inflammatory bowel disease (IBD), the epithelial and 
mucosal barrier function is disturbed, finally leading to a 
chronic relapsing inflammation of the intestinal mucosa.
 Both environmental triggers and genetic susceptibili-
ty have been shown to contribute to the pathophysiology 
of IBD. More than 140 susceptibility loci for IBD have 
been identified mainly by genome-wide association stud-
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 Microparticles are small ( ! 1   m), nonbiological particles that 
are used in many areas of daily life. As food additive they are 
used as anticaking agents or food colorants. The most com-
mon food-derived ingested compounds are aluminium sili-
cate and titanium dioxide (TiO 2 ), the latter being a white pig-
ment used in toothpaste or sugar toppings. The increasing 
abundance of microparticles in the Western diet raises the 
question of the potential risks associated with gastrointesti-
nal diseases such as Crohn’s disease (CD). Accumulation of 
particles has been shown in cells of Peyer’s patches, but it is 
not clear whether this also has pathological effects. NLRP3 is 
a member of the intracellular pattern recognition receptor 
family and it is part of the inflammasome, a multiprotein 
complex containing caspase-1 which activates the proin-
flammatory cytokines interleukin (IL)-1  and IL-18. With re-
gard to recent findings identifying small particles such as as-
bestos and monosodium urate as NLRP3 activators, TiO 2 may 
be another potential target for inflammasome studies. We 
found that macrophage-like cells readily take up TiO 2 after
6 h. Incubation of cells with TiO 2 resulted in the assembly of 
NLRP3 with caspase-1. This inflammasome assembly corre-
lated with secretion of IL-1  . In intestinal epithelial cells, TiO2 
also was found to be ingested. The counting of particles lo-
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ies (GWAS)  [3] , among them a number of genes related to 
innate immune functions including single-nucleotide 
polymorphisms (SNPs) in so-called pattern-recognition 
receptors (PRRs) which recognize microbial patterns
(i.e. pathogen-associated molecular patterns, PAMPs) but 
also other molecular signatures that may be a risk for 
health (so-called danger-associated molecular patterns, 
DAMPs).
 In healthy individuals, activation of PRRs and the sub-
sequent proinflammatory signalling is tightly regulated. 
Among other members of the PRR family, NLRP3 [nu-
cleotide-binding domain-containing and leucine-rich re-
peat-containing (NLR) family and pyrin domain-con-
taining 3 (PYD)], has been shown to play a role in IBD 
etiology. Alternative names for NLRP3 are NALP3, CIAS 
(cold-induced autoinflammatory syndrome 1), PYPAF 
(PYD-containing Apaf1-like) and cryopyrin. In biopsies 
of Crohn’s disease (CD) patients, NLRP3 expression was 
found to be increased  [4] . Besides microbial patterns, 
NLRP3 also recognizes ‘danger signals’ or DAMPS such 
as adenosine triphosphate (ATP)  [5] , asbestos  [6] and uric 
acid crystals  [7] . Upon activation signals, NLRP3 gets as-
sociated with a large multiprotein complex, the NLRP3 
inflammasome, which activates caspase-1. Activated cas-
pase-1 then finally cleaves pro-interleukin (IL)-1  and 
pro-IL-18 ( fig. 1 ).
 Expression of all components of the NLRP3 inflam-
masome has been observed in professional immune cells 
such as macrophages or dendritic cells, but a high level 
has also been found in IECs.
 NLRP3 and Susceptibility to IBD 
 Similar to nucleotide-binding oligomerization do-
main-containing protein 2 (NOD2), the first-identified 
CD susceptibility gene, NLRP3, contains a ‘caspase-re-
cruitment domain’ (CARD) and, upon activation, assem-
bles with caspase-1 to form the inflammasome  [8] . The 
relevance of NLRP3 for CD pathogenesis is obvious from 
the finding that a gain-of-function SNP in NLRP3 and a 
correlating CARD8 loss-of-function SNP both result in a 
protective effect against CD  [9, 10] . NLRP3 gain-of-func-
tion mutations were previously associated with other in-
flammatory diseases and syndromes such as rheumatoid 
arthritis  [11] , Muckle-Wells syndrome, familial cold au-
toinflammatory syndrome  [12] and chronic infantile 
neurological cutaneous and articular syndrome  [13] . All 
are characterized by elevated IL-1  levels, indicating an 
NLRP3/inflammasome activation. Further, NLRP3 was 
shown to be upregulated in colon tissue after the induc-
tion of acute or chronic colitis in mouse models. An ele-
vated expression was also found in colon specimens of 
CD patients  [4] .
 The inflammasome proteins belong to a family of 
NLRs, all sharing common domains that act as intracel-
lular sensors for PAMPs and DAMPs. Similar to Toll-like 
receptors, the NLR family is evolutionarily ancient and 
shares structural homologies with plant resistance (R-) 
proteins. Both protein families have leucine-rich repeat 
(LRR) regions for the recognition of bacterial motifs, an 
oligomerization domain and an effector domain  [14] 
( fig. 2 ).
 Upon activation, NLRP3 assembles into a multiprotein 
complex, recruiting other NLRP3 proteins, CARD8, ASC 
(apoptosis-like speck protein) and caspase-1 ( fig. 1 ). The 
recruitment of caspase-1 triggers its autocatalytic cleavage 
and activation. Subsequently, caspase-1 cleaves pro-IL-1  
or pro-IL-18; this is usually followed by the release of bio-
logically active forms of these cytokines ( table 1 ).
 Fig. 1. NLRP3 inflammasome activation. PAMPs and DAMPs 
such as ROS have been shown to activate the NLRP3 inflamma-
some. Upon activation, NLRP3 assembles to a multiprotein com-
plex together with the adaptor protein, apoptosis-like speck pro-
tein (Asc) and caspase-1. Caspase-1 undergoes autocatalytic acti-
vation, which enables the cleavage of its substrates pro-IL-1  and 
pro-IL-18. The cleaved cytokines are then released by the cell to 
activate downstream targets. 
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 Food-Derived Environmental Factors in the 
Pathogenesis of IBD? 
 IBD cannot only be attributed to genetic factors, as 
monozygotic twins have a concordance rate of only 20–
50% of developing IBD [34–37] . The increased incidence 
of IBD in the last 100 years, the higher incidence of IBD 
in countries with a Western lifestyle and the observed rise 
of IBD in countries recently undergoing ‘westernization’ 
in Asia have led to several hypotheses explaining this 
phenomenon, summarized by Hanauer  [38] . Hygiene, 
diet, social status and smoking are factors potentially in-
fluencing the risk for developing IBD  [39] . Some child-
hood factors such as breastfeeding and childhood infec-
tions are likely to have protective functions, and it has 
been suggested that increased hygienic standards in-
crease the risk of IBD. Another factor associated with a 
typical Western diet is microparticles.
 Microparticles are used as food additives in order to 
influence the color, the consistency or the appearance of 
a product. The most commonly used additives are tita-
nium dioxide (TiO 2 , E171) and aluminium silicate (AlSi, 
E559). Both compounds are sub-micron-sized (0.1–1   m 
diameter) oxides of titanium, silicon or aluminium. 
Since they are inorganic, they are highly stable and resis-
tant to degradation. According to current European leg-
islation, there is no maximum TiO 2 level specified. It is 
recommended that TiO 2 should be used in amounts ac-
cording to good manufacturing practice  [40] . The inter-
national agency for research on cancer published an 
overview on studies addressing the hazardous potential 
of TiO 2 in 2006. In animal studies, inhalation was fol-
lowed by the development of tumors. In vitro studies 
with human alveolar macrophages revealed inhibited 
phagocytosis and DNA damage. Subsequently, TiO 2 was 
rated as possibly carcinogenic for humans (Group 2b) 
 [41] . Classification by the International Agency for the 
 Fig. 2. Domains of the NLR family. In the NLRP subfamily, the 
PYD enables interaction with other proteins, whereas NOD1, 
NOD2, ice protease-activating factor (IPAF) and MHC class II 
transactivator (CIITA) contain CARD domains for interaction. 
Furthermore, LRRs are found at the C-terminus of all NLR fam-
ily members.  AD = Acid transactivation domain; BIR = baculo-
virus inhibitor of apoptosis repeat; FIIND = domain with func-
tion to find; NACHT = domain present in NAIP, CIITA, HET-E, 
and TP-1; NAD = NBD-associated domain; NAIP = NLR family, 
apoptosis inhibitory protein; NALP = NLRP [66].
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e Table 1. A ctivators of the NLRP3 inflammasome (table adapted 
from [15])
Reference
Microorganisms
Sendai virus 09/2006 [16]
Influenza virus 09/2006, 04/2009 [16, 17]
Adenovirus 03/2008 [18]
Staphylococcus aureus 03/2006, 09/2009 [5, 19]
Listeria monocytogenes 03/2006, 05/2008 [5, 20]
Saccharomyces cervisiae 06/2009 [21]
Candida albicans 08/2009 [22]
Aspergillus fumigatus 04/2010 [23]
Bacterial RNA or synthetic
purine bases 03/2006 [24]
Bacterial pore-forming toxins
(aerolysin, maitotoxin and
nigericin)
03/2006,
09/2006, 
11/2006
[5, 25, 26]
Malaria toxin 08/2009 [27]
Danger signals
Extracellular ATP 03/2006 [5]
Hyalorunan 03/2009 [28]
Glucose 12/2009 [29]
Monosodium urate 03/2006 [7]
Amyloid-beta 08/2008 [30]
Silica 08/2008, 07/2008 [31, 32]
Asbestos 07/2008, 05/2008 [6, 32]
Alum 08/2008 [31]
Cholesterol crystals 04/2010 [33]
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Research on Cancer, IARC, as Group 2B. This means 
that the agent is possible carcinogenic in humans but 
there is limited evidence from either animal experiments 
or human studies. In the case of TiO2 there is evidence 
from animal studies but limited evidence from human 
studies.
 Different Microparticles Used in the Food Industry 
 TiO 2 is a white, crystalline powder which is widely 
used as a food supplement in refined food. The pigment 
is used in toothpaste, confectionery, white sauces and 
dressings and nondairy creamers  [42] . In the pharmaceu-
tical industry, it is used as a pill coating. It is inert to most 
influences ( fig. 3 ).
 Iron Oxide 
 Iron oxide (Fe 2 O 3 ) is a nonsoluble, brown and red pig-
ment. It is used as a food colorant as well as in cosmetics. 
The product name is ‘Red luster’ which is also used for 
coating pharmaceutical formulations.
 Titanium Dioxide/Iron Oxide Mixture 
 TiO 2 /Fe 2 O 3 mixture is a gold mica powder. The pow-
der is used as a food colorant and as a coating for phar-
maceutical formulations.
 AlSi 
 AlSi, also known as kaolin, is a natural white, fine-
grained material. The field of application includes the pa-
per-manufacturing industry and powder fabrication, but 
it is also used in the food industry as a carrier substance, 
bleaching product and parting agent, as it prevents cak-
ing ( fig. 3 ).
 Titanium Oxide/AlSi Mixture 
 TiO 2 with potassium (K+) and AlSi added is used as a 
whitener ( fig. 3 ).
 Sources of Dietary Microparticles 
 Microparticles are not declared in the contents of 
many products. The daily intake is difficult to evaluate 
and is highly dependent on the individual diet. Accord-
ing to a study by the European Food Safety Authorities 
(EFSA), the estimated daily intake of TiO 2 is 70–80 mg/
day  [43] . Sources may be tablets, milk whitener and tooth-
paste among others. Other authors estimate the daily in-
gested amount of both TiO 2 and AlSi to be 40 mg or 10 12 
particles/person/day  [44, 45] .
 An overview of sources and estimated amounts of mi-
croparticles is given in  table 2 adapted from  [43, 44] .
 Effects of Titanium Dioxide on Intestinal Epithelial 
Cells 
 Microparticles may penetrate the intestinal barrier 
and accumulate in the mucosa. Early reports on dark, 
pigmented structures in human intestinal lymphoid ag-
gregates date back to 1987  [46] . These structures were lat-
er found to contain high amounts of titanium  [47] . TiO 2 
particles have been shown to accumulate in M cells of 
Peyer’s patches and are passed on to underlying macro-
phages  [48] . Interestingly, the sites of TiO 2 uptake corre-
spond to regions where the first signs of inflammation in 
CD manifest  [49] .
 In vivo studies on the capacity of TiO 2 to penetrate the 
gastrointestinal tract revealed that TiO 2 can be found in 
systemic organs after an oral exposure of 10 days  [50–52] . 
In humans, after a single ingestion of 22 mg and 45 mg of 
TiO 2 , Ti levels in the blood rose after 0.5–2 h and reached 
a maximum after 8–12 h  [52] .
 Clinical studies have also addressed the influence on 
TiO 2 on CD patients. A pilot study performed in 2002 
observed significant decreases in the CD activity index 
 [53] after 4 months on a low-TiO 2 diet. However, a larger 
multicenter double-blind trial was not able to confirm 
these results  [54] . Under present living conditions, a re-
duction or exclusion of dietary TiO 2 may be very difficult. 
With the recent discovery of it being an activator of the 
NLRP3 inflammasome, the influence of TiO 2 on IEC
in the healthy and in the chronically inflamed mucosa 
has gained new interest. Dendritic cells derived from
NLRP3-deficient mice were shown to secrete less IL-1  
upon exposure to TiO 2  [55] . In human keratinocytes and 
in murine macrophages, TiO 2 activated the NLRP3 in-
flammasome  [56] . These data point towards a role of the 
inflammasome as a direct or indirect sensor of TiO 2 .
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 Pathways of NLRP3 Activation 
 It is still not clear how the NLRP3 inflammasome is 
activated in detail. Some authors suggest an initial 
priming event via the NF-  B pathway  [57] . The so-
called DAMPs comprise a group of inflammasome ac-
tivators, and several pathways and mechanisms have 
been shown to be involved in a multistep activation. Re-
cently, Chen and Nunez  [58]  summarized the most im-
portant facts on DAMP-associated inflammasome acti-
vation. Three separate pathways have been suggested. 
The first activation pathway requires high levels of ex-
tracellular ATP. ATP may be released by apoptotic/ne-
crotic cells and trigger the opening of the purinergic 
receptor P2X, ligand-gated ion channel 7 (P2RX7). This 
channel triggers the formation of pores in the cell mem-
brane that allow an efflux of K+ ions. Inflammasome 
activation can be prevented by high concentrations of 
extracellular K+  [32, 59] .
a b c
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Table 2. S ources of microparticles in food products and estimated 
daily intake
Source mg/person/day
TiO2
Food supplement tablet 37.5
Confectionary 24.4
Medicinal product tablet 15.0
Coffee whitener  0.52
Hard coated candies  0.32
Chewing gum  0.28
Marshmallows  0.27
Low-fat or fat-free dressings  0.22
AlSi
Salt  1.30
Drinking chocolate powder  1.26
Chewing gum  0.92
Sugar, icing  0.30
 Fig. 3. Different microparticles in light
microscopy. The examined microparticles 
TiO 2 ( a ), a mixture of TiO 2 and iron oxide 
( b ), iron oxide ( c ), AlSi ( d ) and a mixture 
of TiO 2 and AlSie, were diluted to 100   g/
ml and investigated with a light micro-
scope. Scale bar: 100   m. 
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 The second pathway may be relevant for uric acid crys-
tals (similar to cholesterol crystals), which induce in-
flammasome activation by a different mechanism  [7, 33] . 
These crystals are taken in lysosomes by cells such as 
macrophages. As they cannot be degraded, lysosomal 
damage occurs followed by release of the lysosomal pro-
tease cathepsin B which, in turn, triggers NLRP3 activa-
tion. The lysosomal rupture may cause the production of 
reactive oxygen species (ROS)  [60, 61] . In line with this, 
the activation of the inflammasome, and subsequently 
caspase-1, in response to asbestos crystals was partially 
prevented when ROS synthesis was inhibited  [6] . Release 
of ROS is a danger signal for surrounding cells, and 
NLRP3 has been shown to be activated by necrotic cells. 
In the third concept of inflammasome activation, ROS is 
regarded to be the most important trigger. ROS may act 
both as extracellular and intracellular danger signals.
 Microparticles and Inflammasome Activation 
 Under in vitro conditions we found microparticles 
consisting of TiO 2 intracellularly in IEC and macrophages 
already at low concentrations ( fig. 4 ). Their intracellular 
accumulation did not dependent on endocytosis. TiO 2 ag-
gregates were not restricted to a specific subcellular struc-
ture as observed by electron microscopy. The incubation 
of macrophages and IEC with low concentrations of TiO 2 
resulted in assembly of the NLRP3 inflammasome, and 
correspondingly, the downstream effectors caspase-1, IL-
1  and IL-18 were activated and secreted. High doses of 
TiO 2 caused the generation of ROS in the tested cell types, 
as previously reported for other particulate structures  [6] . 
In contrast to other findings with silica crystals  [31] , the 
uptake of TiO 2 did not lead to lysosomal rupture.
 Increased levels of functionally active IL-18 in IEC 
from CD patients are indicative of an increased inflam-
masome activation. This is in line with findings of other 
groups reporting the transcriptional upregulation of IL-
18 and increased protein levels of mature IL-18 in the mu-
cosa of CD patients  [62, 63] .
 TiO 2 has thus far mainly been the subject of studies 
focusing on effects of inhalation exposure. However, mi-
croparticles are also ingested on a daily basis in the West-
ern diet and their use as food additive is on the rise and 
not limited by food laws. The long-term impact of dietary 
microparticles such as TiO 2 and AlSi has not been stud-
ied, and the risk evaluation is inconclusive. Given that 
TiO 2 is also used in pharmaceutical pills, one can assume 
that local luminal concentrations of TiO 2 can reach sub-
stantial amounts. Depending on the properties of the 
pills, they disintegrate in different sections of the gastro-
intestinal tract and may affect the intestinal epithelium 
in a very distinct and concentrated manner.
 Further work should include other dietary micropar-
ticles such as AlSi and Fe 2 O 3 and evaluate their capacity 
to activate the NLRP3 inflammasome and proinflamma-
tory signalling in macrophages and in IEC. Preliminary 
data show that, for instance, Fe 2 O 3 may be too large to 
penetrate the cells. An effect of TiO 2 on epithelial cells 
that has been reported by others was the reduction of 
transepithelial resistance  [64, 65] .
a b c
 Fig. 4. Eosin-stained cells stimulated with TiO 2 . TiO 2 particles could be found intracellularly. The most frequent uptake of particles 
could be detected in cells at the margin of the monolayer. Scale bars: 50   m ( a , b ) and 20   m ( c ). 
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 Excluding microparticles from food could be a way to 
improve the well-being of IBD patients. Therefore, it 
would be worthwhile to initiate further studies with IBD 
patients to reevaluate the impact of dietary microparti-
cles on the disease activity.
 Conclusion 
 The immune function of IEC is a large field of re-
search, and it has become evident that these cells play an 
important role as a first line of defense, but also function 
as signal inducers for underlying immune cells. The tight 
regulation of proinflammatory and anti-inflammatory 
signalling is an important feature of IEC, which is out of 
balance in the state of chronic intestinal inflammations. 
The emerging role of genetic variations leading to an in-
creased susceptibility to develop IBD is overwhelming, 
but the actions of many susceptibility genes are not fully 
understood.
 The discovery of NLRP3 as a platform for the recogni-
tion of various microorganisms and the more recent rev-
elations on the nonbacterial activators of NLRP3 have 
gained much attention in recent years. The identification 
of TiO 2 microparticles as activators of the NLRP3 in-
flammasome shows that not only immune cells, but also 
IEC are responsive to nonbacterial stimuli. The current 
data suggest that TiO 2 triggers inflammation, ROS and, 
at high concentrations, also apoptosis. Since TiO 2 is con-
sumed as a white pigment in a number of foods and phar-
maceutical pills, this finding may evoke questions about 
food safety, especially in the context of IBD. Further in-
vestigation in animal models but also in healthy individ-
uals and IBD patients will help to reevaluate the risk of 
microparticles in our food.
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